Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  temozolomide
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 341 for your search:
Start Over
Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 0 to 30
Sponsor: Other
Protocol IDs: EUDRACT 2005-002618-40, BfArM-4030755, EC-105/05, DKS 2006.01, DK 2008.17, NCT00749723
Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 3 to 21
Sponsor: NCI
Protocol IDs: NCI-2011-02616, CDR0000688443, ACNS0822, U10CA098543, COG-ACNS0822, NCT01236560
Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-9813, CDR0000067512, ECOG-R9813, NCCTG-RTOG-9813, NCT00004259
Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Other
Protocol IDs: EORTC-26981-22981, EORTC-26981, CAN-NCIC-CE3, EORTC-22981, CE3, NCT00006353
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EDOAGL-8725-001, A5921009, NCT00068952
Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C-100-21, NCT00039000
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P03267, NCT00091572
Radiation Therapy or Temozolomide in Treating Patients With Gliomas
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-22033-26033, 2004-002714-11, CAN-NCIC-CE5, TROG 06.01, MRC-BR13, EORTC-22033, EORTC-26033, EudraCT-2004-002714-11, CE5, NCT00182819
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A3671009, NCT00257205
Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0525, CDR0000465183, EORTC-26052, EORTC-22053, NCI-2009-00731, NCT00304031
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LX01-315, NCT00395070
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 65 and over
Sponsor: Other
Protocol IDs: CE6, CAN-NCIC-CE6, EORTC-26062-22061, TROG 08.02, SPRI-CAN-NCIC-CE.6, CDR0000547163, EORTC-26062, EORTC-22061, NCT00482677
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: EMD 121974-011, EORTC 26071-22072, 2007-004344-78, NCT00689221
Nimotuzumab in Adults With Glioblastoma Multiforma
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: OSAG101-BSA05, NCT00753246
Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme
Phase: Phase III
Type: Health services research, Treatment
Status: Completed
Age: 60 and over
Sponsor: Other
Protocol IDs: CDR0000626713, LEONB-ET2005-006, LEONB-Nordic Glioma Adulte, INCA-RECF0031, EUDRACT-2006-003606-25, SPRI-LEONB-ET2005-006, ET2005-006, NCT00820963
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-01670, RTOG-0825, CDR0000640428, U10CA180868, U10CA021661, NCT00884741
Radiation Therapy With Concomitant and Adjuvant Temozolomide or Radiation Therapy With Adjuvant PCV or Temozolomide Alone in Treating Patients With Anaplastic Glioma
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Temporarily closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: NCCTG-N0577, NCI-2011-01915, EORTC-26081-22086, EudraCT-2008-007295-14, CDR0000640442, N0577, NCT00887146
Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: IcmLCBT_301, NCT00807027
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EF-14, NCT00916409
A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: BO21990, 2008-006146-26, NCT00943826
Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Status: Temporarily closed
Age: No age specified
Sponsor: Other
Protocol IDs: CPT-SIOP-2009, NCT01014767
Efficacy and Safety Study of Lomustine/Temozolomide Combination Therapy vs. Standard Therapy for Glioblastoma Patients
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 70
Sponsor: Other
Protocol IDs: CeTeG, 2009-011252-22, NCT01149109
Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX110-04, NCT01480479
Start Over